Carl Kilander
Partner at HealthCap
Greater Stockholm Metropolitan Area
Overview
Work Experience
Partner
2021 - Current
Medical Associate
2019 - 2021
Director Board of Directors
2023
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Raised $85,000,000.00 from HealthCap, RA Capital Management, Forbion Capital Partners and OrbiMed.
Director Board Of Directors
2022
Director, Board of Directors
2022
Director, Board of Directors
2020
Director Board of Directors
2021
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Raised $166,500,000.00 from Cowen Healthcare Investments, Johnson & Johnson Innovation – JJDC, HealthCap, Northpond Ventures, Biotechnology Value Fund and Cowen Healthcare Investments.
Researcher
2017 - 2020
Ph.D. Candidate
2012 - 2017
My research project adress biliary tract cancer, disease epidemiology and risk factor profiling. Publication examples: Kilander, Carl; Mattsson, Fredrik; Ljung, Rickard; Lagergren, Jesper; Sadr-Azodi, Omid.Systematic underreporting of the population-based incidence of pancreatic and biliary tract cancers. In: Acta Oncologica, Vol. 53, No. 6, 06.2014, p. 822-829.
Medical Intern
2013 - 2014
Co-Founder & CEO
2016 - 2019
Medify.life
Resident
2015 - 2019
Medical doctor
2011 - 2013
Typical work in surgical ED and emergency wards including rounds, surgical operations and trauma management.
Education
Doctor of Philosophy - PhD
2012 - 2017
ATLS
2012 - 2012
Medical doctor (M.D)
2006 - 2011